// App-Quantinova.ai

2745 : Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Researchers

Presenter

  • Ranjana H. Advani

Principal Investigators

  • Pauline Brice

  • Dana A. Kennedy

  • Andrei R. Shustov

  • Nancy L. Bartlett

  • Joseph D. Rosenblatt

  • Tim Illidge

  • Jeffrey V. Matous

  • Radhakrishnan Ramchandren

  • Michelle A. Fanale

  • Joseph M. Connors

  • Yin Yang

Medical Centers

  • The Christie Hospital, Manchester, United Kingdom

  • Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  • Hematology/Oncology, Hopital Saint Louis, Paris, France

Locations

  • France

  • Canada

  • United Kingdom

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral neuropathy

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • T-cell lymphoma

  • Constipation

  • Neutropenia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • monomethyl auristatin E

  • Adcetris

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Doxorubicin

  • Prednisone

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT00866047

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved